Visceral Pain Treatment Market

Visceral Pain Treatment Market, By Drug Type (Pain Modifiers (Tricyclic Anticonvulsant and Tricyclic Antidepressants), Analgesics (Narcotics and NSAID), and Others) By Indications (Chronic prostatitis, Interstitial cystitis, Crohn’s Disease, and Irritable Bowel Syndrome) and By Distribution Channels (Hospital Pharmacy, Retail Pharmacy, and Online Channels ) By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

Visceral pain results from the activation of nociceptors in the viscera (organs) of the pelvis, chest, or abdomen. Visceral structures are very sensitive to stretching (stretching), inflammation, and ischemia, but moderately sensitive to other stimuli that often cause pain such as burning or cutting. Symptoms of visceral pain include vomiting, nausea, changes in vital signs, and emotional manifestations. Pregabalin or gabapentin are some drugs used to treat visceral pain. Visceral pain is defined as internal pain caused by inflammation of internal organs such as the uterus, stomach, rectum, and bladder. This inflammation is caused by several factors such as infection, trauma, and external or internal injuries to internal organs. Visceral pain varies in intensity from sharp, constant, or occasionally deep, like urgent at the body.

Market Dynamics

Increasing number of treatments of visceral pain are expected to drive the global visceral pain treatment market growth. For instance, on December 31, 2022, American Journal of Physiology published an article stating there are few effective treatments for chronic pain. The opioid crisis emphasizes the urgent need to clarify the mechanisms of chronic pain and to develop new forms of treatment that do not have the unacceptable side effects of opioids. Acute pain is a physiological process that is necessary for survival because it allows the awareness and avoidance of injury. Chronic pain can accompany disease (e.g., cancer, inflammatory diseases, functional GI disorders, and diabetes), injury (e.g., neurotrauma) and therapy (e.g., chemotherapy), and can persist after patient the patient is healed. In the visceral organs, pain receptors are not as closely packed and not as evenly spread out as in other organs, which makes the pain’s origin much harder to pinpoint and treat.

Key features of the study:

• This report provides an in-depth analysis of the global visceral pain treatment market and provides market size (US$ Bn) and Compound Annual Growth Rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global visceral pain treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• The key companies covered as a part of this study include Addex Therapeutics Ltd., AstraZeneca, Astellas Pharma Inc., Allergan, Chromocell Corporation, Takeda, GIcare Pharma Inc., Abbvie, Grunenthal GmbH, Johnson & Johnson, Neurim Pharmaceuticals Ltd, and Medestea Research & Production S.p.A.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global visceral pain treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global visceral pain treatment market

Detailed Segmentation:

• Global Visceral Pain Treatment Market, By Drug Type:
• Pain modifiers
• Tricyclic Anticonvulsant
• Tricyclic Antidepressants
• Analgesics
• Narcotics
• NSAID
• Others
• Global Visceral Pain Treatment Market, By Indication:
• Chronic Prostatitis
• Interstitial Cystitis
• Crohn’s Disease
• Irritable Bowel Syndrome
• Global Visceral Pain Treatment Market, By Distribution Channel:
• Hospital Pharmacy
• Retail Pharmacy
• Online Channels
• Global Visceral Pain Treatment Market, By Region:
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• U.K.
• Germany
• France
• Spain
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• North Africa
• Central Africa
• South Africa
• Company Profiles
• Addex Therapeutics Ltd.
• AstraZeneca
• Astellas Pharma Inc.
• Allergan
• Chromocell Corporation
• Takeda
• GIcare Pharma Inc.
• Abbvie
• Grunenthal GmbH
• Johnson & Johnson
• Neurim Pharmaceuticals Ltd
• Medestea Research & Production S.p.A